RxDoctor Payments Data

Grace Kim, MD

Endocrinology, Diabetes & Metabolism · San Carlos, CANPI 1083634323

Payments from drug & device makers

$13,822in general payments, 2019–2025

Across 803 payments — averaging $17.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$3K
  • Novo Nordisk$2K
  • Amgen$2K
  • AstraZeneca$740
  • Bayer$642
  • Boehringer Ingelheim$584
  • plus $5K from 39 others

What the payments were for

  • Food & beverage$13,763100%
  • Education$590%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,822 in reported general payments places this provider in the 75th percentile of 952 endocrinology, diabetes & metabolism providers in California.

See all endocrinology, diabetes & metabolism providers in California

Medicare billing

Part B allowed, 2024
$484,357
Medicare patients
674
Services billed
2,809

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide457$769,584
MounjaroTirzepatide306$585,140
JardianceEmpagliflozin320$408,872
TrulicityDulaglutide186$314,490
Synjardy XrEmpagliflozin/Metformin Hcl140$191,062
JanuviaSitagliptin Phosphate108$133,311
RybelsusSemaglutide61$122,259
Tresiba Flextouch U-200Insulin Degludec53$76,542
Tresiba Flextouch U-100Insulin Degludec116$73,193
FarxigaDapagliflozin Propanediol60$67,679
ProliaDenosumab33$55,762
Xigduo XrDapaglifloz Propaned/Metformin42$49,437
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog31$48,571
KerendiaFinerenone30$44,391
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/726$35,748

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog$2,644$908,239516 claims
Novo NordiskOzempic, Rybelsus$2,400$891,844518 claims
Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Glyxambi$584$649,274498 claims
MerckJanuvia$192$133,311108 claims
AstraZenecaFarxiga$740$67,67960 claims
AmgenProlia$1,675$55,76233 claims
BayerKerendia$642$44,39130 claims
AbbVieSynthroid$152$20,133203 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 952 endocrinology, diabetes & metabolism providers in California.

Other endocrinology, diabetes & metabolism in San Carlos

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →